Active Fibroblast Growth Factor 23 (FGF23)
ADHR; HYPF; HPDR2; PHPTC; Phosphatonin; Tumor-derived hypophosphatemia-inducing factor
- Product No.APA746Mu01
- Organism SpeciesMus musculus (Mouse) Same name, Different species.
- Buffer FormulationPBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- Traits Freeze-dried powder
- Purity> 95%
- Isoelectric Point9.8
- ApplicationsCell culture; Activity Assays.
- Downloadn/a
- UOM 10µg50µg 200µg 1mg 5mg
- FOB
US$ 187
For more details, please contact local distributors! US$ 468 US$ 936 US$ 2808 US$ 7020
ACTIVITY TEST
Fibroblast growth factor 23 (FGF23) is a 3032 kDa member of the FGF family, within a subfamily that also includes FGF19 and FGF21. FGF23 is produced by osteocytes and osteoblasts in response to high circulating phosphate levels, elevated parathyroid hormone, and circulatory volume loading and it plays a central role in chronic kidney disease-mineral bone disorder and is associated with CKD progression and cardiovascular morbidity. Researches show that FGF23 can directly targets cardiac myocytes via Fibroblast Growth Factor Receptor 4 (FGFR4), thereby inducing hypertrophic myocyte growth and the development of left ventricular hypertrophy (LVH) in rodents. Thus a functional binding ELISA assay was conducted to detect the interaction of recombinant mouse FGF23 and recombinant human FGFR4. Briefly, biotin-linked FGF23 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100 ul were then transferred to FGFR4-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST 3 times and incubation with Streptavidin-HRP for 30min, then wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 µl stop solution to the wells and read at 450 nm immediately. The binding activity of FGF23 and FGFR4 was shown in Figure 1, the EC50 for this effect is 0.074 ug/mL.
USAGE
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
STORAGE
Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.
STABILITY
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
GIVEAWAYS
INCREMENT SERVICES
- BCA Protein Quantification Kit
- Molecular Mass Marker for Protein
- Monoclonal Antibody Customized Service
- Polyclonal Antibody Customized Service
- Protein Activity Test Experiment Service
- Electrophoretic Mobility Shift Assay (EMSA) Experiment Service
- Buffer
- Lentivirus Packaging Experiment Service
- Adenovirus Packaging Experiment Service
- Real Time PCR Experimental Service
- Spike RBD Protein (S-RBD)
- Protein G
- Protein A
Magazine | Citations |
Journal of international medicine | Prognostic impact of renal function in precapillary pulmonary hypertension Pubmed: 24011362 |
BMC Nephrology | FGF-23 associated with the progression of coronary artery calcification in hemodialysis patients Pubmed: 24180481 |
Journal of Clinical Densitometry | Lower Fibroblast Growth Factor 23 Levels in Young Adults With Crohn Disease as a Possible Secondary Compensatory Effect on the Disturbance of Bone and Mineral Metabolism Pubmed: 23623649 |
J Intern Med. | Prognostic impact of renal function in precapillary pulmonary hypertension. Pubmed:24011362 |
Journal of Bone and Mineral Research | Adverse effects of osteocytic constitutive activation of ?-catenin on bone strength and bone growth Pubmed:25639729 |
Nefrologia | Fibroblast growth factor is associated to left ventricular mass index, anemia and low values of transferrin saturation El factor de crecimiento fibroblástico está asociado con el índice de masa ventricular izquierda, anemia y niveles bajos de saturación de la transferrina PubMed: 26394828 |
Medicine (Baltimore) | An Attempt to Evaluate Selected Aspects of “Bone–Fat Axis” Function in Healthy Individuals and Patients With Pancreatic Cancer PubMed: 26266370 |
Ann Biol Clin (Paris) | Les biomarqueurs des calcifications vasculaires: quelles limites analytiques pour leur transfert de la recherche bioclinique à la pratique? PubMed: 26069069 |
Scandinavian Journal of Gastroenterology | High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23 Pubmed:27326766 |
PLOS ONE | Prostaglandin-E2 Mediated Increase in Calcium and Phosphate Excretion in a Mouse Model ofDistal Nephron Salt Wasting. pubmed:27442254 |
Journal of Laboratory Diagnostics | Evaluation of concentration fibroblast growth factor FGF-23 in hemodialysed patients and after kidney transplantation publication:312592751 |
Journal of Integrative Nephrology & Andrology | Associations between serum fibroblast growth factor 23 level and intradialytic hypotension in hemodialysis patients issn:2394-2916 |
Journal of Renal Nutrition | ADAM17, a New Player in the Pathogenesis of Chronic Kidney Disease-Mineral and Bone Disorder. pubmed:29056164 |
Experimental Biology and Medicine(Maywood) | Effect of cross-linked chitosan iron (III) on vascular calcification in uremic rats Pubmed:29763365 |
Psychiatry Research | Cerebrospinal fluid FGF23 levels correlate with a measure of impulsivity Pubmed:29677623 |
BMC Pediatrics | Serum and urine FGF23 and IGFBP-7 for the prediction of acute kidney injury in critically ill children Pubmed:29907141 |
Medical Science Monitor | Effect of Salt Intervention on Serum Levels of Fibroblast Growth Factor 23 (FGF23) in Chinese Adults: An Intervention Study Pubmed:29608553 |
International Journal of Chronic Obstructive Pulmonary Disease | Disconnection of pulmonary and systemic arterial stiffness in COPD Pubmed:29881265 |
Saudi journal of kidney diseases and transplantation | Prevalence of cardiac arrhythmia and risk factors in chronic kidney disease patients Pubmed:29970732 |
Nephrology Dialysis Transplantation | High-serum phosphate and parathyroid hormone distinctly regulate bone loss and vascular calcification in experimental chronic kidney disease Pubmed: 30189026 |
BioFactors | Alteration in serum concentrations of FGF19, FGF21, and FGF23 in patients with urothelial carcinoma Pubmed: 30334297 |
Biological Trace Element Research | Altered Mineral Metabolism and Disequilibrium Between Calcification Promoters and Inhibitors in Chronic Hemodialysis Patients Pubmed: 30847765 |
Clin Implant Dent Relat Res. | Evaluation of FGF‐23 and 25(OH)D3 levels in peri‐implant sulcus fluid in peri‐implant health and diseases Pubmed: 31407857 |
JACC-Cardiovascular Imaging | PREVALANCE AND PROGRESSION OF CARDIOVASCULAR CALCIFICATIONS IN HAEMODIALYSIS PATIENTS Pubmed: 28797410 |
Saudi J Kidney Dis Transpl | Serum fibroblast growth factor 23 levels do not correlate with carotid intima-media thickness in patients with chronic kidney disease Pubmed: 31696838 |
Biomedicine & Pharmacotherapy | MiRNA-192-5p attenuates airway remodeling and autophagy in asthma by targeting MMP-16 and ATG7 Pubmed: 31918268 |
Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis? | |
THE RELATIONSHIP BETWEEN ARTERIAL STIFNESS AND 25-(OH) VITAMIN D, FGF 23 IN MAINTENANCE HEMODIALYSIS PATIENTS | |
THE RELATIONSHIP BETWEEN ARTERIAL STIFFNESS AND 25-(OH) VITAMIN D, FGF 23 IN MAINTENANCE HEMODIALYSIS PATIENTS KRON?K ¡ | |
Calcif Tissue Int | The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations Pubmed:35665817 |
European Journal of Medical Genetics | Genetic and clinical profile of patients with hypophosphatemic rickets Pubmed:35738466 |
African Health Sciences | Fibroblast Growth Factor 23 (FGF 23) and intact parathyroid hormone (iPTH) as markers of mineral bone disease among Nigerians with non-diabetic kidney disease |
Catalog No. | Related products for research use of Mus musculus (Mouse) Organism species | Applications (RESEARCH USE ONLY!) |
RPA746Mu01 | Recombinant Fibroblast Growth Factor 23 (FGF23) | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA746Mu03 | Recombinant Fibroblast Growth Factor 23 (FGF23) | Positive Control; Immunogen; SDS-PAGE; WB. |
APA746Mu03 | Active Fibroblast Growth Factor 23 (FGF23) | Cell culture; Activity Assays. |
RPA746Mu02 | Recombinant Fibroblast Growth Factor 23 (FGF23) | Positive Control; Immunogen; SDS-PAGE; WB. |
APA746Mu01 | Active Fibroblast Growth Factor 23 (FGF23) | Cell culture; Activity Assays. |
PAA746Mu02 | Polyclonal Antibody to Fibroblast Growth Factor 23 (FGF23) | WB; IHC; ICC; IP. |
PAA746Mu01 | Polyclonal Antibody to Fibroblast Growth Factor 23 (FGF23) | WB; IHC; ICC; IP. |
MEA746Mu | Mini Samples ELISA Kit for Fibroblast Growth Factor 23 (FGF23) | Enzyme-linked immunosorbent assay for Antigen Detection. |
SEA746Mu | ELISA Kit for Fibroblast Growth Factor 23 (FGF23) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA746Mu | Multiplex Assay Kit for Fibroblast Growth Factor 23 (FGF23) ,etc. by FLIA (Flow Luminescence Immunoassay) | FLIA Kit for Antigen Detection. |
KSA746Mu01 | ELISA Kit DIY Materials for Fibroblast Growth Factor 23 (FGF23) | Main materials for "Do It (ELISA Kit) Yourself". |